Safety Requirements for Contraceptive Steroids

Part 1 Analysis of effects in humans: the epidemiological assessment of the safety of hormonal contraceptives - a methodological review, D.C.G.Skegg; the breast, D.B.Thomas; the ovary and endometrium, E.Medina; hormonal contraceptives and the risk of cervical cancer, B.S.Hulka; epidemiological assessment of effects of steroidal contraceptives on the liver and gall bladder, P.R.Kenya; epidemiological assessment of cardiovascular effects of hormonal contraception, L.Heinemann; effects on pregeny of exposure to hormonal contraceptives prior to conception "in utero" or through breast milk, S.Harlap; effects of contraceptive steroids in humans - lessons learnt from epidemiology, M.P.Vessy. Part 2 Analysis of animal toxicology: the toxicological assessment of the safety of hormonal contraception, R.Heywood; comparative endocrinology, J.K.Hodges; comparative endocrine pharmacodynamics of contraceptive steroids, M.F.Etreby et al; comparative pharmacokinetics of selected contraceptive steroids, M.Humpel; predictability of the safety of hormonal contraceptives from canine toxicological studies, K.S.Larsson; sub-human primate studies, M.G.Valerio; teratogenicity studies of sex hormones, A.G.Hendrick and P.E.Biaterd; lessons learnt from toxicology, C.L.Berry. Part 3 Clinical research and post-registration surveillance: strategies for post-registration surveillance of contraceptive steroids, D.B.Petitti and S.Shapiro; effect of disease and drug interactions on the response to oral contraceptive steroids, A.M.Breckenridge et al; metabolic effects of contraceptive steroids, J.S.Bajaj et al; metabolic and cardiovascular aspects of oral contraceptives, A.Rosseneu; cardiovascular complication with the use of low-oral contraceptives in Finland, E.Hirvonen and J.Idanpaan-Heikkila; lessons learnt from clinical trials, C.W.Bardin.